Description
Aspirin, an affordable and widely accessible antithrombotic, provides modest but meaningful benefits in secondary stroke prevention. Large randomized controlled trials show aspirin reduces the risk of early recurrent stroke within 2–4 weeks by about 12%, and lowers death or dependency by around 5%. Over longer-term use, aspirin decreases the risk of recurrent stroke by approximately 17% in patients with prior TIA or ischaemic stroke. Observational studies suggest even greater benefits—up to 80% risk reduction—when aspirin is used urgently after TIA or minor stroke.